Shares of Novavax, Inc. (NASDAQ:NVAX) ended Friday session in red amid volatile trading. The shares closed down -7.05 points or -84.53% at $1.29 with 242.23 million shares getting traded. Post opening the session at $1.17, the shares hit an intraday low of $1.16 and an intraday high of $1.68 and the price vacillated in this range throughout the day. The company has a market cap of $54.11 million and the numbers of outstanding shares have been calculated to be 271.19 million shares.
Novavax, Inc. (NVAX) announced it will host its 4th annual Investor and Analyst Meeting, Tuesday, October 11, 2016 from 9:00 a.m. – 11:00 a.m. ET in New York, NY.
Senior management will conduct a series of presentations to update analysts and investors on the Company`s ongoing clinical development programs. In addition, a key opinion leader will provide a clinical perspective on respiratory syncytial virus (RSV) disease.
Novavax expects to announce data from its pivotal Phase 3 trial of the RSV F Vaccine in older adults in the third quarter of 2016.
For additional information and registration, please email firstname.lastname@example.org or call 443-213-0506.
A live webcast of the presentations can be accessed under the “Investors”/ “Events” section of the Novavax website at novavax.com. Please allow extra time prior to the webcast to visit the site and download the streaming media software required to listen to the Internet broadcast. The webcast and a replay of the presentation will also be accessible under the “Investors/Events” section of the Novavax website at novavax.com. The event will be archived on the company`s website for 90 days.
Shares of Skyline Medical Inc (NASDAQ:SKLN) ended Friday session in green amid volatile trading. The shares closed up +0.033 points or 19.63% at $0.200 with 35.62 million shares getting traded. Post opening the session at $0.17, the shares hit an intraday low of $0.17 and an intraday high of $0.20 and the price vacillated in this range throughout the day. The company has a market cap of $19.47 million and the numbers of outstanding shares have been calculated to be 81.80 million shares.
Skyline Medical Inc (SKLN) on Sept. 08, 2016 announced the appointment of Paul Sweetnam, Ph.D. to the Company’s Medical Advisory Board (MAB). Dr. Sweetnam brings to Skyline’s MAB more than 25 years of executive and entrepreneurial experience in the pharmaceutical and biotechnology industries. In addition, Dr. Sweetnam has established an extensive network of scientific collaborators within academia, the government and industry.
Skyline Medical’s MAB was formed in July 2013 and provides guidance and advice to the Company to support its product development goals. Including Dr. Sweetnam, the MAB has five members.
“We are delighted that a scientist of Dr. Sweetnam’s stature has agreed to join our MAB,” said Dr. Carl Schwartz, chairman and interim chief executive officer of Skyline Medical. “His impressive credentials include a track record of identifying and integrating disruptive technologies such as high-throughput and profile screening into the drug discovery and development process. We are looking forward to being able to leverage Dr. Sweetnam’s capabilities as we explore the use of the STREAMWAY System filter as a method of sample collection for rapid diagnostics and biomarker identification in the operating room.”
Dr. Sweetnam is the founder of CellBridge, LLC, a partnership between Nano Terra Life Sciences, where he previously served as Chief Technology Officer, and the United States Biological Corporation. CellBridge was organized to investigate three-dimensional cell-based assays for drug development and personalized medicine applications, and Dr. Sweetnam is leading a Department of Defense-funded initiative to develop novel treatments for peripheral nerves. He also currently serves on the External Advisory Board of the Graduate School of Biomedical Science and Engineering at the University of Maine.
Earlier in his career Dr. Sweetnam was Chief Scientific Officer of Surface Logix, a drug development company founded by renowned Harvard scientist Prof. George M. Whitesides. Dr. Sweetnam’s work with Prof. Whitesides’ portfolio included microfluidics, soft lithography and cell biology. Dr. Sweetnam also has worked at Bayer Healthcare as Vice President of Research Technologies and at Pfizer as Manager in the Drug Pfinder Department of Research Licensing and Operations, among others positions.